UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

27 UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

Read More Share:

Jun

14 How UCB Is Supporting the Mental Health of Patients and Caregivers

Read More Share:

Jun

14 Recognizing Ethical Leadership at UCB

Read More Share:

Jun

02 Prioritizing Mental Health as a Caregiver to a Child With Dravet Syndrome

Read More Share:

Jun

01 Myasthenia Gravis Awareness Month is the Time to Understand More About the Lived Experiences of the Community

Read More Share:

Apr

27 Voices on Value: Breaking Down the Value Chain: The Policies Impacting Patients

Read More Share:

Apr

21 Earth Day 2023: Our Commitment to Sustainability in the Workplace

Read More Share:

Apr

20 UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

Read More Share:

Apr

18 How Shared Decision-Making Creates Better Patient-Provider Collaboration in Dermatology

Read More Share:

Apr

17 UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Read More Share:

Categories

Archives

Jun

27

UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

Jun

14

How UCB Is Supporting the Mental Health of Patients and Caregivers

Jun

14

Recognizing Ethical Leadership at UCB

Jun

02

Prioritizing Mental Health as a Caregiver to a Child With Dravet Syndrome

Jun

01

Myasthenia Gravis Awareness Month is the Time to Understand More About the Lived Experiences of the Community

Apr

27

Voices on Value: Breaking Down the Value Chain: The Policies Impacting Patients

Apr

21

Earth Day 2023: Our Commitment to Sustainability in the Workplace

Apr

20

UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

Apr

18

How Shared Decision-Making Creates Better Patient-Provider Collaboration in Dermatology

Apr

17

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Choose Country

UCB in the U.S.

Patients

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Jun

27

UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

Jun

14

How UCB Is Supporting the Mental Health of Patients and Caregivers

Jun

14

Recognizing Ethical Leadership at UCB

Jun

02

Prioritizing Mental Health as a Caregiver to a Child With Dravet Syndrome

Jun

01

Myasthenia Gravis Awareness Month is the Time to Understand More About the Lived Experiences of the Community

Apr

27

Voices on Value: Breaking Down the Value Chain: The Policies Impacting Patients

Apr

21

Earth Day 2023: Our Commitment to Sustainability in the Workplace

Apr

20

UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

Apr

18

How Shared Decision-Making Creates Better Patient-Provider Collaboration in Dermatology

Apr

17

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Disease Areas

Sustainability

Newsroom

Contact